PATENT CLAIM ANALYSIS

Application Number: 16142969
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "220000"]

Abstract:
The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.

Claim (Index 20):
The method of  claim 19 , wherein the compound of Formula II is selected from:\n 6,6-dimethyl-4-phenyl-9-methyl-6H-thieno[3,2-f]-s-triazolo[4,3-a][1,4]diazepine; 4-(3\u2032,4\u2032-methylenedioxyphenyl)-9-methyl-6H-thieno[3,2-f]-s-triazolo[4,3-a][1,4]diazepine; 9-methyl-4-phenyl-6H-thieno[3,2-f]-s-triazolo[4,3-a][1,4]diazepine; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 97.0
- Lexical Diversity: 1.31915
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15066513', '11670238', '14513281', '13257082', '13265060']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7137761015473074
- 35 USC 102 Novelty (BERT): 0.6322504077603189
- Combined Prediction Score: 0.7056235321686085
- Mean Citation Score: 395.297994
- Max Citation Score: 685.7202
- Similarity Product: 500.6812908643484

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test